| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.7 | $0-$5k | 0.00 |
Summary
A vulnerability, which was classified as problematic, has been found in IBM Curam Social Program Management. This vulnerability affects unknown code. Performing a manipulation results in cross site scripting. This vulnerability is identified as CVE-2016-0261. The attack can be initiated remotely. There is not any exploit available. It is advisable to upgrade the affected component.
Details
A vulnerability classified as problematic has been found in IBM Curam Social Program Management (Business Process Management Software) (affected version unknown). This affects an unknown functionality. The manipulation with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. The summary by CVE is:
Cross-site scripting (XSS) vulnerability in IBM Curam Social Program Management 6.0.0 before SP2 EP29, 6.0.4 before 6.0.4.6 iFix3, 6.0.5 before 6.0.5.9 iFix2, 6.1.0 before 6.1.0.1 iFix1, and 6.1.1 before 6.1.1.1 iFix1; and IBM Care Management 6.0 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors. IBM X-Force ID: 110604.
The bug was discovered 04/14/2016. The weakness was released 03/12/2018 (Website). The advisory is shared at exchange.xforce.ibmcloud.com. This vulnerability is uniquely identified as CVE-2016-0261 since 12/08/2015. It is possible to initiate the attack remotely. The successful exploitation needs a authentication. Neither technical details nor an exploit are publicly available. MITRE ATT&CK project uses the attack technique T1059.007 for this issue.
The vulnerability was handled as a non-public zero-day exploit for at least 697 days. During that time the estimated underground price was around $5k-$25k.
Upgrading eliminates this vulnerability.
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
Product
Type
Vendor
Name
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.8VulDB Meta Temp Score: 4.7
VulDB Base Score: 4.3
VulDB Temp Score: 4.1
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔍
Timeline
12/08/2015 🔍04/14/2016 🔍
03/12/2018 🔍
03/12/2018 🔍
03/13/2018 🔍
02/21/2023 🔍
Sources
Vendor: ibm.comAdvisory: exchange.xforce.ibmcloud.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2016-0261 (🔍)
GCVE (CVE): GCVE-0-2016-0261
GCVE (VulDB): GCVE-100-114381
X-Force: 110604
Entry
Created: 03/13/2018 07:40Updated: 02/21/2023 10:13
Changes: 03/13/2018 07:40 (58), 01/12/2020 15:29 (1), 02/21/2023 10:07 (4), 02/21/2023 10:13 (1)
Complete: 🔍
Cache ID: 216::103
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
No comments yet. Languages: en.
Please log in to comment.